Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00217503
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 13
- Registration Number
- NCT00216697
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193232
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193557
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00182637
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00153933
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Winship Cancer Center, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT00153920
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 38
- Registration Number
- NCT00148317
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-07-10
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 37
- Registration Number
- NCT00148018
- Locations
- 🇩🇪
University of Cologne, Cologne, NRW, Germany
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-10-26
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 87
- Registration Number
- NCT00136591
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇧🇪Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.